GSK2982772 is primarily investigated for its potential in treating inflammatory and autoimmune diseases. It functions as a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), a key enzyme involved in inflammation and cell death pathways. Due to this mechanism, it has been studied in conditions such as rheumatoid arthritis, psoriasis, and ulcerative colitis. By blocking RIPK1, the compound helps reduce the production of pro-inflammatory cytokines, thereby mitigating tissue damage and disease progression. Clinical trials have explored its oral bioavailability and safety profile, showing promise as a targeted therapy with fewer side effects compared to broad immunosuppressants. Its development represents a step toward precision medicine in chronic inflammatory disorders.